Search results
Results from the WOW.Com Content Network
(Reuters) -Shares of British drugmaker GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer ...
GSK shares dropped to their lowest since January on Thursday. The stock was among the bottom performers in the FTSE 100 index and Europe's STOXX 600. It was down around 4.8% at 1432 GMT.
GSK shares were down 2.2% at 1213 GMT, set for their biggest one-day fall in a month and the largest weighted drag on the FTSE 100.
(Reuters) -GSK's blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday. Oncology ...
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Unilever's shares fell nearly 7 percent on Monday after it confirmed its interest in the consumer health division of GlaxoSmithKline. Analysts think a tie-up would be unwise.
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock. Glaxo (GSK) Shares Continue to Witness Upside ...